Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling Back
Novo Nordisk

Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company.
Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling BackGlob.Revenue, mln.USD
33709
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year.
The Company Statement
May 23, 2023
Suspend further marketing and clinical investment; pause new clinical trials and active enrollment but increased revenue in Russia in 2022 vs 2021. Danish diabetes care giant Novo Nordisk (NOV: N) has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of year 2024. Revenue decreased in 2024 vs 2023 by more than -10%.
| January 14, 2026 | Novo Nordisk trying to stop exports of Russian generic of Ozempic |
| December 29, 2025 | Novo Nordisk Seeks to Block Russian Export of Ozempic Copycat |
| May 24, 2025 | Geropharm will be able to produce its analogues of Ozempic until the end of 2025 |
| February 18, 2025 | The copycat brands that are replacing Ozempic in Russia |
| December 26, 2024 | Russians spent almost 6 billion rubles on generics of ozempic |
| November 19, 2024 | PSK Pharma received government permission to produce an analogue of Ozempic |
| December 15, 2023 | An analogue of Ozempic went on sale despite the patent |
| October 06, 2023 | The first analogue of a drug for glucose control has been registered in Russia |
| March 29, 2022 | https://www.novonordisk.com/news-and-media/critical-updates.html |
| March 29, 2022 | Novo Nordisk to stop supplies of diabetes drug Ozempic to Russia this year |
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Scanner